Bile duct cancer (Cholangiocarcinoma) – Pipeline Review, 2019

Bile duct cancer, also called cholangiocarcinoma is a rare form of cancer that develops when abnormal cells in the surface of the bile duct grow in a metastatic nature. The higher prevalence of liver fluke infection along with other diseases such as cirrhosis, diabetes, and chronic viral hepatitis B and C infections has led to the increase in the incidents of bile duct cancer (cholangiocarcinoma) in countries of Asia Pacific. According to the American Cancer Society, an estimated 8,000 individuals in the U.S are diagnosed with bile duct cancer annually.

Currently, a surgery that completely removes the tumor is the only potentially curative treatment for cholangiocarcinoma. However, numerous pharmaceutical players and the government organizations are involved in smoothening the path for the development of novel therapeutics for cholangiocarcinoma. Chemotherapeutic options include prescription of drugs like 5-fluorouracil, Cisplatin, Gemcitabine among others.

Over 110 ongoing clinical studies for the treatment of cholangiocarcinoma are anticipated to drive the survival gains of patients suffering from the disease. Novel approaches are being developed by pharmaceutical companies, medical universities, government authorities such as NHS for the clinical trials on new as well as existing therapeutic molecules.

As of 2018, an estimated 88% of the pipeline candidates for bile duct cancer (Cholangiocarcinoma) are in the phase-2 and phase-3 clinical stage. Projected 13 % of the pipeline candidates are in Phase 3 clinical stage. Additionally, an anticipated 52% of the studies are sponsored by industry.

Report Description

The report on ‘Bile duct cancer (Cholangiocarcinoma) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bile duct cancer (Cholangiocarcinoma). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bile duct cancer (Cholangiocarcinoma).

The report on ‘Bile duct cancer (Cholangiocarcinoma) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Bile duct cancer (Cholangiocarcinoma)


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Bile duct cancer (Cholangiocarcinoma)


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary